Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

• DOI: 10.1200/jco.22.02545
• Publication Date: 2023-05-17T22:00:46Z
• Authors: Frances A. Shepherd; Janet Dancey; Rodryg Ramlau; Karin Mattson; Richard Gralla; Mark O’Rourke; Nathan Levitan; Laurent Gressot; Mark Vincent; Ronald Burkes; Susan Coughlin; Yong Kim; Jocelyne Berille
• Keywords: Adult; Male; Chi-Square Distribution; Lung Neoplasms; Paclitaxel; Palliative Care; Antineoplastic Agents; Docetaxel; Middle Aged; Antineoplastic Agents, Phytogenic; 3. Good health; Carboplatin; 03 medical and health sciences; 0302 clinical medicine; Carcinoma, Non-Small-Cell Lung; Disease Progression; Quality of Life; Humans; Female; Prospective Studies; Cisplatin; Aged; Proportional Hazards Models

To evaluate whether treatment with single-agent docetaxel would result in longer survival than best supportive care patients non-small-cell lung cancer who had previously been treated platinum-based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality life.